PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineWilliam P. Tew, Elise C. Kohn, Monica B. Jones et al.|Journal of Clinical Oncology|2020Cited by 318
Pegylated liposomal doxorubicin (PLD) with bevacizumab (B) in second-line treatment of ovarian cancer (OC): Pharmacokinetics (PK), safety, and preliminary outcome resultsFranco M. Muggia, Claire F. Verschraegen, Leslie R. Boyd et al.|Journal of Clinical Oncology|2009Cited by 10
Prevention of Gynecologic MalignanciesDavid S. Alberts, Joan L. Walker, Richard R. Barakat et al.|Gynecologic Cancer|2004Cited by 3